Mass. biotechs ripe for buyouts

Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an $8.8 billion bid for Millennium Pharmaceuticals. And the Boston Business Journal wonders which Massachusetts-based company is next on the buyout hit-list?

Cubist Pharmaceuticals, Epix Pharmaceuticals and Alynlam Pharmaceuticals, to name a few. Biogen Idec could be an acquisition target for a large biotech. According to MassBIO, 189 of the state's companies have drugs in Phase II, and another 69 have Phase III drug in the works. As one investment banker observes, up to three dozen Massachusetts drug developers could be up for grabs.

- see the Boston Business Journal report

Related Articles:
Pharma goes mad for biotech deals
Pharma noshes at the biotech buffet
Big Pharma makes its big leap into biotech
Dealmaking stays big even as the markets tremble